August 31, 2020 Comments Off on Investor Alert: Pieris Pharmaceuticals, Inc. (PIRS)  Blog, Current Investigations

Investor Alert: Pieris Pharmaceuticals, Inc. (PIRS) 

Pieris Pharmaceuticals, Inc. (PIRS) Investment Losses, featured by top securities fraud attorneys, The White Law Group

Concerned about your investment in Pieris Pharmaceuticals, Inc.?

Are you concerned about your investment in Pieris Pharmaceuticals, Inc. (PIRS)? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

Pieris Pharmaceuticals, Inc., based in Boston, MA, is a clinical-stage biotechnology company, which reportedly engages in the discovery and development of Anticalin-based drugs.

The company filed a form D to raise capital from 139 investors in 2014, according to filings with the SEC. The total offering amount sold was purportedly $13,559,020.

According to the SEC filings, two placement agents and their designees received cash commissions in the aggregate of up to 8% of the offerings gross proceeds and five-year warrants to purchase an aggregate of 8% of the number of shares sold in the offering.

According to Market Watch, as of August 31, shares of PIRS are down more than 44% in the past 12 months. 

Filing a Complaint against your Brokerage Firm

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.

The problem with pharmaceutical investments such as Pieris Pharmaceuticals Inc. is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.

Without a strong understanding of the company and its basic operations, investors may be looking at serious losses.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in Pieris Pharmaceuticals, Inc. please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

Comments are closed.